<DOC>
	<DOCNO>NCT02297529</DOCNO>
	<brief_summary>The study phase 3b , multicenter , open-label , single-arm study design provide expand access Talimogene Laherparepvec treatment subject unresected stage IIIB IVM1c melanoma . The study also evaluate safety tolerability Talimogene Laherparepvec .</brief_summary>
	<brief_title>Expanded Access Study Talimogene Laherparepvec Treatment Subjects With Unresected Stage IIIB-IVM1c Melanoma</brief_title>
	<detailed_description>This phase 3b , multicenter , open-label , single-arm , expand access study talimogene laherparepvec treatment subject unresected stage IIIB IVM1c melanoma select European country . Subjects unresected stage lllB-IVM1c melanoma eligible access ongoing talimogene laherparepvec clinical trial meet eligibility criterion outline consider participation protocol . Eligible subject treat talimogene laherparepvec subject achieve complete response , injectable tumor disappear , clinically relevant ( result clinical deterioration require change therapy ) disease progression beyond 6 month therapy , intolerance protocol treatment , talimogene laherparepvec receive market authorization approval Europe treatment melanoma , whichever occur first . Subjects follow safety approximately 30 ( +7 ) day end treatment . Thereafter , subject provide consent follow ongoing separate registry protocol long-term survival follow-up subject treat talimogene laherparepvec clinical trial . The registry protocol also monitor late long-term adverse event think potentially related talimogene laherparepvec .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>1 . Provide informed consent prior initiation protocolspecific activities/procedures . 2 . Male female age â‰¥ 18 year time inform consent . 3 . Histologically confirm diagnosis melanoma 4 . Subject unresected stage lllB IVM1c melanoma regardless prior therapy 5 . Subject eligible access ongoing talimogene laherparepvec clinical trial 6.Subject qualify , access , comparable satisfactory alternative therapy stage IIIB IVM1c melanoma 7 . Candidate intralesional therapy 8 . Adequate organ function . 9 . ECOG performance status 0 , 1 , 2 . 1 . Clinically active cerebral metastasis . 2 . Greater 3 visceral metastasis . 3 . Bone metastases 4 . Primary ocular mucosal melanoma . 5 . History evidence symptomatic autoimmune pneumonitis , glomerulonephritis , vasculitis , symptomatic autoimmune disease . 6 . Active herpetic skin lesion prior complication HSV1 infection ( eg , herpetic keratitis encephalitis ) 7 . Known acute chronic active hepatitis B C infection 8 . Known human immunodeficiency virus infection 9 . History malignancy within past 3 year 10 . Female subject pregnant breastfeeding , plan become pregnant protocol treatment 3 month last dose talimogene laherparepvec 11 . Female subject childbearing potential unwilling use acceptable method ( ) effective contraception protocol treatment 3 month last dose talimogene laherparepvec . 12 . Subject know sensitivity product component administer dose . 13 . Subject enter protocol previously .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>unresected , Melanoma , expand access , EU</keyword>
</DOC>